Spots Global Cancer Trial Database for The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor
Official Title: Study on the Application of ctDNA in a Population at High-risk for Common Malignant Tumor
Study ID: NCT04405557
Conditions
Interventions
Study Description
Brief Summary: This is a observational, multicenter study, monitoring the circulating tumor DNA (ctDNA) in people who is at risk of cancers，assessing the sensitivity and specificity of ctDNA detection in early screening of pan-carcinoma.
Detailed Description: 2000 patients with positive tumor protein markers or cancer screening were recruited. All patients were tested for ctDNA at enrollment and followed up at 6 months and 1 year. The study was completed at the time of cancer diagnosis or the longest follow-up time (1 year).
Keywords
Eligibility
Minimum Age: 45 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Chinese PLA General Hospital, Beijing, Beijing, China
Shenzhen People's Hospital, Shenzhen, Guangdong, China
Henan Provincial People's Hospital, Zhengzhou, Henan, China
Xiangya Hospital Central South University, Changsha, Hunan, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
China-Japan Union Hospital of Jilin University, Changchun, Jilin, China
The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
Contact Details
Name: Qiang Zeng, MD
Affiliation: Chinese PLA General Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
